|Bid||54.70 x 800|
|Ask||60.21 x 800|
|Day's range||56.13 - 58.33|
|52-week range||28.55 - 81.91|
|Beta (5Y monthly)||1.40|
|PE ratio (TTM)||49.76|
|Earnings date||28 Jul 2020 - 03 Aug 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||67.19|
Other than Reline 3D, NuVasive's (NUVA) Reline System portfolio has products like Reline Open, Reline MAS, Reline Trauma and Reline Small Stature.
Investors are optimistic about NuVasive (NUVA) on continued momentum across several recently-launched products as well as solid international business.
Image source: The Motley Fool. NuVasive Inc (NASDAQ: NUVA)Q1 2020 Earnings CallMay 6, 2020, 4:30 p.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGreetings, and welcome to the NuVasive, Inc.
NuVasive (NUVA) delivered earnings and revenue surprises of 37.14% and 0.05%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Those holding NuVasive (NASDAQ:NUVA) shares must be pleased that the share price has rebounded 35% in the last thirty...
To the annoyance of some shareholders, NuVasive (NASDAQ:NUVA) shares are down a considerable 47% in the last month...
To the annoyance of some shareholders, NuVasive (NASDAQ:NUVA) shares are down a considerable 30% in the last month...
Last week, you might have seen that NuVasive, Inc. (NASDAQ:NUVA) released its full-year result to the market. The...
Today we are going to look at NuVasive, Inc. (NASDAQ:NUVA) to see whether it might be an attractive investment...
NuVasive (NUVA) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Abbott's (ABT) imminent quarterly results are expected to reflect a solid performance by the Established Pharmaceuticals Division (EPD) business alike the last reported quarter.
OrganiGram (OGI) is expected to have benefited from its firm focus on building brand equity and ongoing product innovation in the fiscal first quarter.
Edwards Lifesciences' (EW) HemoSphere all-in-one monitoring platform is gaining momentum on the back of a strong rollout that sees a full-market launch.